Top Markets
#1 Black Phoenix Black Phoenix +354.04%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +69.28%
#4 Gold Park Gold Park +58.04%
#5 Acurast Acurast +39.30%
#6 OpenEden OpenEden +35.14%
#7 BasedHype BasedHype +27.14%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.38%
#9 Cryptopia Cryptopia +21.54%
#10 Avantis Avantis +17.76%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Celadon Pharmaceuticals Plc Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc

CEL
Rank in Stocks #40708
Celadon Pharmaceuticals Plc functions as a drug development company,... Celadon Pharmaceuticals Plc functions as a drug development company, concentrating on the discovery, production, and distribution of cannabinoid compounds for certified medical uses. The firm's primary activity involves the indoor, hydroponic cultivation of THC cannabis, which is then incorporated into medicinal products targeting chronic pain. Furthermore, Celadon intends to broaden its research into cannabinoids, exploring their therapeutic applications not only for persistent pain but also for conditions such as autism and multiple sclerosis. Established in 2018, the company maintains its headquarters in London, United Kingdom.
Share Price
$0.00179028
Last synced: 2025-07-28
Market Cap
$94.61K
Change (1 day)
-0.54%
Change (1 year)
0.00%
Country
GB
Trade Celadon Pharmaceuticals Plc (CEL)

Category

Healthcare
P/E ratio for Celadon Pharmaceuticals Plc (CEL)
P/E ratio as of 2026 TTM: 0
According to Celadon Pharmaceuticals Plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Celadon Pharmaceuticals Plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 41.61 -
IN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.